Zimbabwe has rejected a significant American health deal worth 367 million US dollars (272 million pounds) over five years due to the United States' demand for sensitive biological samples.
This move came to light following a official document from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "lopsided".
A government spokesperson later clarified that the US was seeking health data for scientific study and profit while was not willing to share the resulting advantages from future treatments.
"We will now turn to the challenging and unfortunate process of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished over $1.9bn as health assistance to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for further negotiations to secure a agreement agreeable to all parties so the country's critical HIV programme can be sustained.
Wider Context
This rejection comes after a similar situation in neighbouring Kenya, where a high court suspended a related health funding agreement after concerns were raised about the safety of citizens' health data.
Since returning to office recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had managed assistance for the US government, but Trump claimed its spending was "inefficient" and his government was pursuing direct bilateral deals to boost transparency and responsibility.
As per reports, 16 nations in Africa have to date agreed to these new health pacts, constituting more than $18.3bn in committed funds.
Details of the Declined Deal
The funds for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation might have yielded extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on antiretroviral therapy through American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Our nation was requested to surrender its biological resources and data indefinitely, without any equivalent guarantee of access to any medical innovations – like new medicines or tests – that might result from that provided information," he stated.
"Put simply, our nation would provide the raw materials for medical research without any certainty that the end products would be available to our people if a future disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its push of one-on-one health agreements were disrupting frameworks already established via the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to manage future global health emergencies.
"This system is intended to guarantee that when a nation provides its information, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage continued dialogue with our US partners on how subsequent collaboration might be structured in a manner that honours the independence and interests of both nations."
Medical Community Reaction
A leading public health body said it acknowledged the official position, but urged that negotiations should continue since a large portion of the nation's HIV programmes relied on international support.
"If technical issues arise, such as those relating to data governance or implementation frameworks, these can often be addressed via detailed discussion and negotiated safeguards," it commented.
This impasse underscores the ongoing debate between receiving vital foreign assistance and safeguarding a country's data in an ever more data-driven world.